zirconium silicate
Trade name: Lokelma
Small moleculeapproved
Approved
May 18, 2018
Sodium zirconium cyclosilicate, sold under the brand name Lokelma, is a medication used to treat high blood potassium. Onset of effects occurs in one to six hours. It is taken by mouth. — Wikipedia
Clinical trial activity
35 trials · 22 clinical orgs · 2 marketing orgs
Phase 1
3
Phase 2
22
Phase 3
18
Phase 4
7
Earliest trial started Nov 1, 2011 (NCT01493024)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2012
Earliest Phase 3 Sponsor(trial)
- Jan 1, 2017
AstraZeneca — Earliest Phase 1 Sponsor(trial)
- May 18, 2018
AstraZeneca — Earliest FDA Approval
- May 18, 2018
AstraZeneca — Marketing Organization
- May 18, 2018
AstraZeneca — NDA Secondary Org
- May 18, 2018
AstraZeneca — NDA Organization
2020s
- Oct 8, 2025
Alkem Labs Ltd — Marketing Organization
Indications
Approved for
Studied for
- Acidosis · Phase 3
- Arrhythmias, Cardiac · Phase 4
- Chronic Kidney Disease-Mineral and Bone Disorder · Phase 4
- Diabetes Mellitus, Type 2 · Phase 2
- Dialysis · Phase 4
- Diet Therapy · Phase 4
- Drugs, Investigational · Phase 4
- Heart Failure · Phase 3
- Heart Failure, Systolic · Phase 4
- Hyperkalemia · Phase 4
- Hyperparathyroidism, Secondary · Phase 3
- Hypokalemia · Phase 4
- Kidney Diseases · Phase 2
- Myocardium · Phase 4
- Postural Balance · Phase 4
- Renal Insufficiency, Chronic · Phase 4
- Zirconium · Phase 4
Mechanism of action
Approval history
- approvedMay 18, 2018
Chemistry & pharmacology
Loading structure…
SMILES
[Na+].[Na+].[Zr].[O-][Si]1([O-])O[Si]([O-])([O-])O[Si]([O-])([O-])O1- Mol. weight
- 365.455 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- Yes
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaSodium zirconium cyclosilicate ↗
- NCATSD652ZWF066 ↗
- ChEMBLCHEMBL3301592 ↗
- WikipediaZirconium(IV) silicate ↗
Also known as
- everest hpc
- silicic acid (h4si04) zirconium(4+) salt (1:1)
- sodium zirconium cyclosilicate
- sodium zirconium cyclosilicate
- sodium zirconium cyclosilicate
- sodium zirconium cyclosilicate
- sodium zirconium cyclosilicate
- sodium zirconium cyclosilicate
- uxsi-9
- uxsi-9
- ziconite
- zircon
- zirconium cyclosilicate
- zirconium silicate
- zirconium silicate
- zirconium silicate
- zrsio4
- zs
- zs
- zs-9
- zs-9
- zs-9 compound
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06736184 | Phase 4 | Mar 1, 2025 | Shandong Province Qianfoshan Hospital |
| NCT06578078 | Phase 3 | Oct 3, 2024 | University of Valencia |
| NCT06365684 | Phase 4 | Apr 29, 2024 | AstraZeneca, Leiden University |
| NCT06578533 | Phase 3 | Sep 30, 2022 | University of Valencia |
| NCT05347693 | Phase 4 | Mar 24, 2022 | AstraZeneca |
| NCT06242041 | Phase 4 | Feb 14, 2022 | Peking University |
| NCT05056727 | Phase 3 | Sep 30, 2021 | AstraZeneca, Stanford University |
| NCT04789239 | Phase 2 | Sep 1, 2021 | AstraZeneca, Sahlgrenska University Hospital, Sweden, University of Gothenburg |
| NCT05004363 | Phase 3 | Sep 1, 2021 | University of London |
| NCT04997161 | Phase 4 | Aug 17, 2021 | AstraZeneca |
| NCT04983979 | Phase 2 | Aug 15, 2021 | Barts & The London NHS Trust |
| NCT04914962 | N/A | Jul 10, 2021 | Cairo University |
| NCT04847232 | Phase 3 | Apr 30, 2021 | AstraZeneca, North Shore University Hospital |
| NCT04788641 | Phase 1 | Mar 30, 2021 | AstraZeneca, Parexel |
| NCT04727528 | Phase 3 | Mar 22, 2021 | AstraZeneca |
| NCT04727840 | Phase 1 | Mar 15, 2021 | Harvard University |
| NCT04676646 | Phase 4 | Mar 1, 2021 | AstraZeneca |
| NCT04585542 | Phase 4 | Oct 20, 2020 | University of California, Irvine |
| NCT04217590 | Phase 3 | Jun 5, 2020 | AstraZeneca, Jiao Tong University |
| NCT04207203 | N/A | Mar 1, 2020 | AstraZeneca, Karolinska Institute |
Showing 20 of 35 trials
Page 1 / 2
Organizations
Research & Development (22)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 20 | 17 | 5 | 2017 |
| ZS Pharma, Inc. | For profit | 5 | 5 | 2 | 2011 |
| University of Valencia | Academic/Hospital | 2 | 2 | 1 | 2022 |
| Barts & The London NHS Trust | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Baylor University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Karolinska Institute | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Leiden University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| New York University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| North Shore University Hospital | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Parexel | For profit | 1 | 0 | 1 | 2021 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Sahlgrenska University Hospital, Sweden | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Shandong Province Qianfoshan Hospital | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Shantou University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| The Montreal Health Innovations Coordinating Center | For profit | 1 | 0 | 1 | 2018 |
| University of California, Irvine | Academic/Hospital | 1 | 1 | 1 | 2020 |
22 organizations
Page 1 / 2
Marketing (4)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Alkem Labs Ltd | For profit | MKTG | Oct 8, 2025 |
| AstraZeneca | For profit | MKTG | May 18, 2018 |
| AstraZeneca | For profit | NDA2 | May 18, 2018 |
| AstraZeneca | For profit | NDA | May 18, 2018 |